Virios therapeutics issues shareholder letter highlighting corporate progress and key upcoming milestones

Atlanta, ga., feb. 28, 2024 (globe newswire) -- virios therapeutics, inc. (nasdaq: viri) (the “company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“fm”) and long-covid (“lc”), today issued a shareholder letter highlighting the company's progress and key milestones in 2024.
VIRI Ratings Summary
VIRI Quant Ranking